Peptide appearance Lyophilized form

Healing and Regeneration

15 000+ verified orders

KPV

In stock

KPV, a short peptide derived from alpha-melanocyte stimulating hormone (alpha-MSH), displays anti-inflammatory and antimicrobial properties, modulating the production of pro-inflammatory cytokines and chemokines. It holds promise in various disease conditions, particularly in inflammatory bowel disease (IBD) treatment, where it has shown substantial efficacy and safety across multiple administration routes. Additionally, research suggests that KPV may accelerate wound healing, reduce infection, and minimize scarring following surgery. Ongoing investigations into the anti-inflammatory effects of KPV underscore its potential as a valuable therapeutic agent in managing inflammatory disorders.
Available strengths
38,50 €
Buy 2, get 1 free. €100 in paid peptide vials · water excluded
Bundle & save

Arrives 26 – 30 November to Europe

We accept Visa Mastercard Apple Pay (when supported) Google Pay (when supported) Klarna (where available) Shown at checkout

KPV

38,50 €

KPV tripeptide fragment for melanocortin, barrier, and immune-signalling studies.

Compound information

Specifications

Molecular profile

Sequence
Lys-Pro-Val
Molecular mass
342.43 g/mol
CAS number
67727-97-3
Molecular formula
C16H30N4O4

Material record

Physical appearance
White to off-white lyophilized powder
Solubility
Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
Product note
Alpha-MSH tripeptide fragment; supplied strictly for research use only.

Research overview

KPV

Description of KPV

KPV, a tripeptide composed of lysine, proline, and valine, exhibits potent anti-inflammatory properties, although its mechanisms of action have remained elusive. Studies aimed to investigate the role of PepT1, a di/tripeptide transporter, in mediating the anti-inflammatory effects of KPV in intestinal epithelial and immune cells. Results demonstrate that nanomolar concentrations of KPV inhibit NF-kappaB and MAP kinase inflammatory signaling pathways, leading to a reduction in pro-inflammatory cytokine secretion. Notably, KPV acts through PepT1 expressed in both immune and intestinal epithelial cells. Furthermore, oral administration of KPV reduces the incidence of colitis induced by dextran sulfate sodium (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS), highlighting its potential as a research compound in the context of inflammatory bowel disease (IBD). The peptide was studied also for wound healing, scar formation, and other mostly anti-inflammatory properties.

[1], [2]

Overview of Published Research

Mice treated with KPV display markedly diminished colonic infiltration and maintain normal colon lengths compared to control counterparts, underscoring its potential in mitigating inflammatory conditions in research models. Notably, KPV's impact seems concentrated in settings of heightened inflammation, with minimal effect on normal tissue. This selectivity is attributed to its utilization of PepT1, a transporter upregulated during inflammatory states, suggesting KPV's potential interest as a research subject in the context of inflammatory bowel disease (IBD). Furthermore, insights into KPV's mechanism of action propose a novel approach to drug delivery, targeting proteins modulated in disease conditions to concentrate drug activity. This approach holds promise for investigating the reduction of dosage of drugs with severe side effects and developing research compounds tailored to specific disease states.

Professor Didier Merlin's investigations into KPV's gastrointestinal activity have revealed its potential to enter colonic cells via PepT1, predominantly expressed during inflammatory states, elucidating its enhanced activity in inflamed settings. This finding not only supports KPV's candidacy as a research compound for IBD investigation but also unveils a paradigm for drug delivery, exploiting alterations in protein expression to enhance drug localization and activity. Such targeted delivery strategies offer the prospect of minimizing drug dosages with adverse effects while maximizing research impact, opening a new area of investigation in precision approaches for diverse disease states.

[3] - [5]

Studies investigating the effect of α-MSH and related tripeptides, such as KPV, on fever and inflammation underscore their potential as anti-inflammatory research compounds. Specifically, α-MSH has exhibited potent anti-inflammatory and protective effects both in vitro and in vivo, impacting various pathways involved in inflammation regulation and protection. While α-MSH presents pigmentary concerns, its C-terminal tripeptide, KPV, has emerged as a promising alternative for anti-inflammatory research, devoid of pigmentary action yet preserving anti-inflammatory activity. Moreover, K(D)PT, a derivative of KPV, has also demonstrated potent anti-inflammatory effects, offering further research potential in the context of immune-mediated inflammatory diseases affecting the skin, bowel, eyes, and joints.

Research spanning decades has elucidated the anti-inflammatory properties of KPV and its parent molecule, α-MSH, in a diverse array of inflammatory conditions, including fever, dermatitis, vasculitis, arthritis, and gastrointestinal inflammation. While α-MSH remains the most effective anti-inflammatory agent studied, its pigmentary side effects pose limitations. However, KPV's comparative lack of side effects suggests its potential as a research alternative, albeit with slightly reduced potency. Notably, while KPV may be less potent than α-MSH, it still exerts considerable anti-inflammatory effects, particularly in mitigating immediate inflammatory responses. Ongoing research aims to uncover the precise mechanisms underlying these differential responses, providing insights into immune modulation and inflammation regulation.

[6] - [8]

The synthesis and evaluation of His-Phe-Arg-Trp-NH2 and its derivatives have revealed promising antifungal properties, particularly against Cryptococcus neoformans, suggesting a potential research avenue in investigating fungal infections. These tetrapeptides exhibit antifungal activity akin to alpha-melanocyte-stimulating hormone (α-MSH), and theoretical calculations have elucidated their biologically relevant conformation and minimal structural requirements for antifungal response, guiding future compound design. Moreover, α-MSH and its derivatives, like KPV, have garnered research interest for their activity in wound healing, particularly in minimizing scar formation and fostering a more regenerative healing process.

Recent studies highlight the potential of α-MSH analogues, such as KPV, in influencing wound healing outcomes by reducing inflammation and promoting scarless healing. Alpha-MSH's anti-inflammatory activity, mediated via the melanocortin 1 receptor (MC-1R), has been associated with its ability to modulate immune responses and influence tissue repair. Analogues like KPV offer anti-inflammatory and antimicrobial properties, representing a promising research approach for wound healing investigation without inducing undesirable pigmentation or inhibiting the body's natural defense mechanisms against infection. Furthermore, ongoing research explores the structural basis of KPV's antifungal effects, suggesting its potential as a structural model for the development of novel antifungal research compounds with improved activity and selectivity.

[9] - [11]

Skin wound healing is a complex process in adult mammals, often resulting in scar tissue formation. Alpha-melanocyte-stimulating hormone (α-MSH) is distributed widely in the central nervous system and skin, exhibiting strong anti-inflammatory activity. The study aimed to assess whether intraperitoneal injection of α-MSH before skin wounds could reduce inflammation and influence wound healing in adult mice. Adult mice received an injection of 1 mg/kg of α-MSH before creating skin wounds. Wound healing was evaluated macroscopically and microscopically over 60 days. α-MSH reduced leukocytes, mast cells, and fibroblasts at 3 and 7 days post-injury, while also decreasing scar area and improving collagen fiber organization at days 40 and 60, indicating its potential to promote a more regenerative wound healing pathway in the studied model.

The research on modulatory effects of NDP-MSH, analogue of α-MSH, in regenerating rat livers post partial hepatectomy (PH) reveals its potential to influence liver molecular changes induced by surgery. NDP-MSH treatment significantly altered the expression of various transcripts, including chemokines, receptors, and cell cycle mediators, influencing critical signaling pathways like the interleukin-6 (IL-6)/signal transducer and activator of transcription (STAT)/suppressor of cytokine signaling (SOCS) axis. While NDP-MSH did not substantially affect the final organ regeneration, it exerted subtle influences on hepatocyte replication and gene expression, suggesting its potential effects during liver regeneration research.

In experimental heart transplantation, NDP-alpha-MSH, a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), demonstrated protective activity by influencing various molecular pathways associated with heart function preservation. The peptide induced expression of cytoskeleton proteins, intracellular kinases, and transcription regulators while repressing immune and inflammatory mediators, leading to down-regulation of oxidative stress response and up-regulation of ion channels and metabolic pathways. These findings suggest that NDP-alpha-MSH may be of research interest in the context of organ transplantation by influencing heart function through its broad effect on multiple pathways, including both Ag-dependent and -independent injury.

Additionally, research on acute lung injury induced by bleomycin instillation in rats highlights the research potential of NDP-alpha-MSH in reducing inflammation and pulmonary edema. The peptide treatment mitigated bleomycin-induced transcriptional alterations in genes involved in stress response, inflammation, and fluid homeostasis, leading to a significant reduction in interstitial edema and down-regulation of proinflammatory and profibrotic factors.

[11] - [15]

α-Melanocyte-stimulating hormone (α-MSH) has emerged as a potent anti-inflammatory mediator, acting via melanocortin receptors (MC-Rs) expressed in various tissues. It modulates inflammatory responses through pathways like NF-κB activation, cytokine expression, and T-cell activity. While effective, its pigment-inducing capacity limits its use in research. However, its C-terminal tripeptide, KPV, preserves anti-inflammatory properties without inducing pigmentation. Despite lacking MC-R binding motifs, KPV exhibits significant anti-inflammatory effects, making it a promising candidate for research into peptide compounds in immune-mediated inflammatory diseases like skin conditions, bowel diseases, asthma, and arthritis.

Studies comparing KPV with core MSH peptides reveal distinct anti-inflammatory mechanisms. Unlike core peptides, KPV's effects are not mediated through MC-Rs, suggesting alternative pathways such as IL-1β inhibition. Moreover, transdermal delivery studies highlight KPV's potential for diverse administration routes in research settings. While alpha-MSH is more potent, KPV's lack of side effects and ease of administration make it a subject of research interest. Its broad anti-inflammatory effects and multiple administration routes offer versatility in targeting different areas of the body in research models, promising further investigation into inflammatory disorder mechanisms.

[16] - [18]

All presented information is based on scientific publications which can be found in

For laboratory purposes and personal observation only. Not for human consumption.

Laboratory care

Handling

Peptides in transport

Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.

Storage of lyophilized peptides

Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Up to 3 months
  • Refrigerated (2–8 °C): Up to 6 months
  • Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)

Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.

Storage of reconstituted peptides

Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.

The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Avoid prolonged storage
  • Refrigerated (2–8 °C): Typically 4–8 weeks
  • Frozen (-20 °C or below): Up to 3–4 months

To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.

Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.

Analytical documentation

Tests

Latest published result

Liquilabs s.r.o.Signed Certificate of Analysis · 10mg

Certificate preview for 10mg

> 99.8%Purity by HPLC

Batch number
2027602
Tested
2026-09-08

Recorded QC panel

AssayPeptide Screening 0.1% TFA
10.48 mg (± 0.05 mg)
PurityPeptide Screening 0.1% TFA
> 99.8%
Identity (FTIR)Peptide Screening 0.1% TFA
995 (± 5)
Identity (RT)Retention time
0.984 (± 0.005)
Bacterial endotoxinUSP 85 / Eur. Ph. 2.6.14
0.157 EU/mg

These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.

See all test results

Signed certificate

Source record

References

1.

G. Dalmasso et al., "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation", 2008

2.

M. E. Hiltz and J. M. Lipton, "Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH," FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol., vol. 3, no. 11, pp. 2282–2284, Sep. 1989.

3.

K. Kannengiesser et al., "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease," Inflamm. Bowel Dis., vol. 14, no. 3, pp. 324–331, Mar. 2008, doi: 10.1002/ibd.20334.

4.

B. Xiao et al., "Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis," Mol. Ther. J. Am. Soc. Gene Ther., vol. 25, no. 7, pp. 1628–1640, 05 2017, doi: 10.1016/j.ymthe.2016.1020.

5.

G. Dalmasso, L. Charrier-Hisamuddin, H. T. T. Nguyen, Y. Yan, S. Sitaraman, and D. Merlin, "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation," Gastroenterology, vol. 134, no. 1, pp. 166–178, Jan. 2008, doi: 10.1053/j.gastro.2007.10.026.

6.

D. B. Richards and J. M. Lipton, "Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit," Peptides, vol. 5, no. 4, pp. 815–817, Aug. 1984, doi: 10.1016/0196-9781(84)90027-5.

7.

T. Brzoska, T. A. Luger, C. Maaser, C. Abels, and M. Böhm, "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases," Endocr. Rev., vol. 29, no. 5, pp. 581–602, Aug. 2008, doi: 10.1210/er.2007-0027.

8.

T. A. Luger and T. Brzoska, "α‐MSH related peptides: a new class of anti‐inflammatory and immunomodulating drugs," Ann. Rheum. Dis., vol. 66, no. Suppl 3, pp. iii52–iii55, Nov. 2007, doi: 10.1136/ard.2007.079780.

9.

M. Cutuli, S. Cristiani, J. M. Lipton, and A. Catania, "Antimicrobial effects of alpha-MSH peptides," J. Leukoc. Biol., vol. 67, no. 2, pp. 233–239, Feb. 2000, doi: 10.1002/jlb.67.2.233.

10.

M. F. Masman et al., "Synthesis and conformational analysis of His-Phe-Arg-Trp-NH2 and analogues with antifungal properties," Bioorg. Med. Chem., vol. 14, no. 22, pp. 7604–7614, Nov. 2006, doi: 10.1016/j.bmc.2006.07.007.

11.

K. S. de Souza et al., "Improved cutaneous wound healing after intraperitoneal injection of alpha-melanocyte-stimulating hormone," Exp. Dermatol., vol. 24, no. 3, pp. 198–203, Mar. 2015, doi: 10.1111/exd.12609.

12.

C. Lonati et al., "Modulatory effects of NDP-MSH in the regenerating liver after partial hepatectomy in rats," Peptides, vol. 50, pp. 145–152, Dec. 2013, doi: 10.1016/j.peptides.2013.10.014.

13.

G. Colombo et al., "Gene expression profiling reveals multiple protective influences of the peptide alpha-melanocyte-stimulating hormone in experimental heart transplantation," J. Immunol. Baltim. Md 1950, vol. 175, no. 5, pp. 3391–3401, Sep. 2005, doi: 10.4049/jimmunol.175.5.3391.

14.

G. Colombo et al., "Production and effects of alpha-melanocyte-stimulating hormone during acute lung injury," Shock Augusta Ga, vol. 27, no. 3, pp. 326–333, Mar. 2007, doi: 10.1097/01.shk.0000239764.80033.7e.

15.

M. Schiller et al., "Human Dermal Fibroblasts Express Prohormone Convertases 1 and 2 and Produce Proopiomelanocortin-Derived Peptides," J. Invest. Dermatol., vol. 117, no. 2, pp. 227–235, Aug. 2001, doi: 10.1046/j.0022-202x.2001.01412.x.

16.

T. Brzoska, M. Böhm, A. Lügering, K. Loser, and T. A. Luger, "Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore," Adv. Exp. Med. Biol., vol. 681, pp. 107–116, 2010, doi: 10.1007/978-1-4419-6354-3_8.

17.

S. J. Getting, H. B. Schiöth, and M. Perretti, "Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides," J. Pharmacol. Exp. Ther., vol. 306, no. 2, pp. 631–637, Aug. 2003, doi: 10.1124/jpet.103.051623.

18.

K. Pawar, C. S. Kolli, V. K. Rangari, and R. J. Babu, "Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin," J. Pharm. Sci., vol. 106, no. 7, pp. 1814–1820, Jul. 2017, doi: 10.1016/j.xphs.2017.03.017.

19.

National Center for Biotechnology Information

PubChem Compound Summary: Lys-Pro-Val

Authoritative identity record for the KPV tripeptide.

PubChem View source ↗
20.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · 2008

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

Primary study of KPV transport and signalling in an experimental model.

Gastroenterology · 10.1053/j.gastro.2007.10.026 View source ↗
21.

Chemical Abstracts Service

CAS Common Chemistry: 67727-97-3

Authoritative CAS Registry Number record for KPV.

CAS Common Chemistry View source ↗
22.

National Center for Biotechnology Information

PubChem compound record

PubChem View source ↗
23.

Luger TA, Brzoska T · 2007

alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs

Annals of the rheumatic diseases View source ↗
24.

Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D · 2017

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis

Molecular therapy : the journal of the American Society of Gene Therapy · 10.1016/j.ymthe.2016.1020 View source ↗
25.

M. E. Hiltz and J. M. Lipton · 1989

Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH

FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol
26.

K. Kannengiesser et al. · 2008

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

Inflamm. Bowel Dis · 10.1002/ibd.20334 View source ↗
27.

D. B. Richards and J. M. Lipton · 1984

Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit

Peptides · 10.1016/0196-9781(84)90027-5 View source ↗
28.

T. Brzoska, T. A. Luger, C. Maaser, C. Abels, and M. Böhm · 2008

Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases

Endocr. Rev · 10.1210/er.2007-0027 View source ↗
29.

T. A. Luger and T. Brzoska · 2007

α‐MSH related peptides: a new class of anti‐inflammatory and immunomodulating drugs

Ann. Rheum. Dis · 10.1136/ard.2007.079780 View source ↗
30.

M. Cutuli, S. Cristiani, J. M. Lipton, and A. Catania · 2000

Antimicrobial effects of alpha-MSH peptides

J. Leukoc. Biol · 10.1002/jlb.67.2.233 View source ↗
31.

M. F. Masman et al. · 2006

Synthesis and conformational analysis of His-Phe-Arg-Trp-NH2 and analogues with antifungal properties

Bioorg. Med. Chem · 10.1016/j.bmc.2006.07.007 View source ↗
32.

K. S. de Souza et al. · 2015

Improved cutaneous wound healing after intraperitoneal injection of alpha-melanocyte-stimulating hormone

Exp. Dermatol · 10.1111/exd.12609 View source ↗
33.

C. Lonati et al. · 2013

Modulatory effects of NDP-MSH in the regenerating liver after partial hepatectomy in rats

Peptides · 10.1016/j.peptides.2013.10.014 View source ↗
34.

G. Colombo et al. · 1950

Gene expression profiling reveals multiple protective influences of the peptide alpha-melanocyte-stimulating hormone in experimental heart transplantation

J. Immunol. Baltim. Md 1950 · 10.4049/jimmunol.175.5.3391 View source ↗
35.

G. Colombo et al. · 2007

Production and effects of alpha-melanocyte-stimulating hormone during acute lung injury

Shock Augusta Ga · 10.1097/01.shk.0000239764.80033.7e View source ↗
36.

M. Schiller et al. · 2001

Human Dermal Fibroblasts Express Prohormone Convertases 1 and 2 and Produce Proopiomelanocortin-Derived Peptides

J. Invest. Dermatol · 10.1046/j.0022-202x.2001.01412.x View source ↗
37.

T. Brzoska, M. Böhm, A. Lügering, K. Loser, and T. A. Luger · 2010

Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore

Adv. Exp. Med. Biol · 10.1007/978-1-4419-6354-3_8 View source ↗
38.

S. J. Getting, H. B. Schiöth, and M. Perretti · 2003

Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides

J. Pharmacol. Exp. Ther · 10.1124/jpet.103.051623 View source ↗
39.

K. Pawar, C. S. Kolli, V. K. Rangari, and R. J. Babu · 2017

Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin

J. Pharm. Sci · 10.1016/j.xphs.2017.03.017 View source ↗

Customer reviews

4.7/5185+ reviews
View on Trustpilot ↗Checked 17 Nov 2026

Quality products,fast shipping,great refferal plan,only downside is that products in 4 mounths since my first order got more and more expensive ,but overall verry good experience.

Read full review →

More than 2 weeks for package dispatch. They promised one free peptide next time. Sent me new tracking number but package still wasn't delivered to fedex. Last package (much much cheaper) was delivered in less than week. I will update if they will send my package. ok,package sent.

Read full review →

Extremely satisfied with the product quality and overall experience. The customer service is polite and quick. All recommendations!

Read full review →

Trustworthy site with a huge catalog of products. Been purchasing from them for some time now never got disappointed. I could only recommend them.

Read full review →

Everything ok. With little problem with package, but after contact with Customer Service everything went right. Good quality of products

Read full review →

Excellent. Buying peptides online can be nerve wracking! But Adria are very transparent about all the checks and certifications. My experience with them was excellent. Great products at good prices and efficient P&P

Read full review →